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Abstract: Innovation in stroke rehabilitation technology is discussed that, 
based on published epidemiological and economic data, represents an urgent 
case to deal with adopting a multidisciplinary perspective. A theoretical model 
is proposed for the evaluation of socioeconomic implications related to an early 
diagnosis and early and timely adjustments in the stroke treatment strategy. The 
model is applied to the case of a new rehabilitation technology: the ALLADIN 
diagnostic device. The model compares a traditional approach – ‘trial and error 
strategy’ – to the innovative one – ‘in progress evaluation’, considering the 
diagnostic and rehabilitative steps of the patient’s assistive route and assessing 
social and economic benefits of the innovative device. The new technology 
allows a precise initial assessment of both the severity of stroke and the level of 
lost functionality, as long as an evaluation of the expected return from different 
potential therapies. Moreover, supposing that higher severity of stroke implies 
higher level of disabilities and social costs, and that the negative impact 
increases as the level of disability increases, the use of innovative rehabilitation 
technologies would be more effective in the case of patients with severe and 
very severe stroke. 
Keywords: costs; disability; economic evaluation; rehabilitation technology; 
stroke, theoretical model. 
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1 Introduction 
The introduction of new and advanced solutions in the biomedical technology sector is a 
complex process, and it is usually more difficult to achieve than in other fields. Several 
elements, in fact, may be identified as factors contributing to the complexity of the 
innovation process such as the multidimensionality of the problems, the requested 
multidisciplinary approach, the presence of conflicts of interests and resistance in the 
organisations and in the professionals, the differences in the incentives and time horizon 
of various players and stakeholders. The social and ethical implications of health-related 
activities would need also to be considered. Consequently, managing biomedical product 
development process requires to take into account technological, clinical, economic, 
social, ethical and legal perspectives that introduce new constraints/objectives of the 
innovation process such as efficacy, effectiveness, affordability, sustainability, equity, 
usability, market potential and accessibility. 
The paper proposes and discusses a theoretical model for the assessment of social and 
economic benefits of an innovative technology with the aim to frame the cost-saving 
implications related to the use of a new device. The model is applied to the stroke case, 
and it could be generalised to the field of neurological pathologies. Basing on published 
epidemiological and economic data, stroke represents an urgent case to deal with from an 
integrated and multidisciplinary perspective that contributes to well framing the clinical, 
technological and economic scenario in which to move forwards the future/possible 
commercialisation of innovative technological devices for stroke patients. An early 
diagnosis is extremely important in terms of recovering functionality after the stroke 
event, as well as the first months after the occurrence of the disease, requiring an early 
and timely adjustment in the treatment strategy. With the aim of improving and 
increasing the effectiveness of the post-stroke rehabilitation, an innovative method for 
decision support in neurorehabilitation could be achieved through the use of ALLADIN 
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(Natural Language-Based Decision Support In Neuro-Rehabilitation) diagnostic device 
(ADD). The theoretical model proposed in this study compares a traditional approach, 
pursuing a ‘trial and error strategy’, to an ‘in progress evaluation strategy’ carried out by 
ALLADIN, considering the diagnostic and the rehabilitative steps of the assistive route 
for a stroke patient. The model allows a precise assessment of both the severity of stroke 
and the level of lost functionality, as long as an evaluation of the expected returns, 
pointing out the potential social cost savings related to the application of an innovative 
technology for neurorehabilitation in stroke, as the ALLADIN device. 
In order to define the state of the art of innovation in rehabilitation technology and 
approaching the matter from an integrated and multidisciplinary perspective, a review of 
the epidemiological and economic data about stroke has been carried out. In Section 2, 
the main published epidemiological studies have been analysed in order to estimate, 
basing on data about stroke incidence, prevalence, mortality and disability, the full 
market potential of rehabilitation technology. The cost categories of stroke have been 
defined according to the Cost-of-Illness approach, and a critical analysis of the most 
relevant published data about the total – and the social – cost of stroke is proposed in 
order to provide a general frame of costs and potential cost savings related to the use of 
innovative technology for neurorehabilitation in stroke. In Section 3, an outline of the 
procedures in assessing the functional recovery outcome in neurorehabilitation after 
stroke is provided. ADD as a tool supporting the clinical decision making towards the 
choice of the best rehabilitative process for each patient is described. The theoretical 
model is proposed and discussed in Section 4, and it is applied to the ADD, showing the 
social and economic benefits of this new neurorehabilitation technology. Closing remarks 
are finally argued in Section 5. 
2 Epidemiological context of stroke and socioeconomic implications 
According to the World Health Organization (WHO) definition, stroke is a clinical 
syndrome with ‘rapidly developing clinical signs of focal or global disturbance of 
cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no 
apparent cause other than of vascular origin’ (Truelsen, Begg and Mathers, 2003). The 
main subtypes of stroke are identified as ischaemic stroke, haemorrhagic stroke and 
subarachnoid haemorrhage. Baseline stroke severity is assessed using the National 
Institute of Health Stroke Scale, and in agreement with the classification proposed by 
H.S. Jorgensen, it could be distinguished in four levels: mild, moderate, severe and very 
severe (Jorgensen et al., 1999). Epidemiological data on disease occurrence are essential 
for describing the burden of stroke and the post-stroke neurorehabilitation process 
involved. Together with prevalence, incidence, morbidity and mortality data, cost 
estimates help to portray the impact that society or an organisation faces from stroke. 
2.1 Epidemiological context of stroke 
The WHO estimates that every year 15 million people worldwide suffer a stroke. Of 
these, 5 million are left permanently disabled and 5.5 million (3 million women and 2.5 
million men) die (World Health Organization, 2004). In demographically developed 
countries, characterised by an older age structure, the mean age at which stroke occurs is 
around 70 years, while in less developed regions, the average age of stroke will be 
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younger due to the different population age structure resulting from higher mortality rates 
and competing causes of death (Truelsen, Begg, and Mathers, 2003). 
Incidence, prevalence and mortality estimates are quite different in the published 
international and national studies as they strongly depend on the composition of the 
reference population, in relation to age and sex, on type of stroke and the study design. 
Recently, the American Heart Association estimates that each year about 700,000 
people experience a new or recurrent stroke in the USA. About 500,000 of these are 
first attacks. Approximately 200,000 occur in people who have already had a stroke 
before. Men’s stroke incidence rates are greater than women’s at younger ages but not 
at older ages (American Heart Association, 2007). Epidemiological studies have shown 
that incidence differs widely throughout Europe with a gap between eastern and 
western European countries. In 1997, crude incidence rates of acute stroke were higher 
for most eastern (range between 3.0/1,000 and 5.0/1,000) than for western countries 
(range between 2.0/1,000 and 2.5/1,000) (Brainin et al., 2000). The most recent Italian 
guide line Stroke Prevention and Educational Awareness Diffusion (SPREAD) indicates 
that 196,000 cases of stroke occur in Italy every year, 80% of those are first occurrence 
of stroke and 20% are relapses. In all, 39,000 persons with stroke die in the first month 
after the event and other 58,800 survive with disability (SPREAD, 2005). Italian 
population-based crude incidence rates are available for six stroke registries and range 
from 1.79/1,000 in Vibo Valentia to 2.92/1,000 in L’Aquila. Incidence rates increase with 
age; in regard to persons aged from 65 to 84 years, an European population-based study 
indicates that the incidence rate is 8.72/1,000 with a corresponding 95% confidence 
interval (95% CI) between 7.47 and 10.06 (Di Carlo et al., 2000). In the same age 
class, data from the Italian Longitudinal Study on Aging (ILSA), suggests that sex- and 
age-standardised incidence rate of stroke is 10.47/1,000 (95% CI: 8.63–12.32) 
(SPREAD, 2005). 
The American Heart Association reported that among adults aged 20 and older, the 
prevalence of stroke in 2004 was estimated at 5,700,000 (2,400,000 males, 3,300,000 
females) (American Heart Association, 2007). Prevalence rates increase with age, and 
consistently across age classes, men have higher rates than women. The prevalence rates 
given in the European survey did not show uniform differences between eastern and 
western countries. Individuals over 65 years have higher prevalence rates of stroke, 
varying between 4.61 and 7.33%, as reported by international population-based studies 
(Feigin et al., 2003). The ILSA study estimates that sex- and age-standardised prevalence 
rate of stroke is 6.5% (95% CI: 4.9–6.9) in persons aged from 65 to 84 years. Prevalence 
is higher in men (7.4%; 95% CI: 6.3–8.5) than in women (5.9%; 95% CI: 4.9–6.9) and 
increases with age (SPREAD, 2005). 
Stroke is the third most common cause of death in developed countries, exceeded 
only by coronary heart disease and cancer, accounting for 10% of all deaths (9% of all 
male deaths and 11% of all female deaths), that is about 400,000 deaths per year in the 
European community countries. Stroke is the second leading cause of death above the age 
of 60 years and the fifth leading cause in people aged 15 to 59 years (Hachinski, 2002). 
Stroke accounted for about one of every 16 deaths in the USA in 2004. About 50% of 
stroke deaths in 2003 occurred out of hospital. There was 150,147 (58,660 males, 91,487 
females) stroke-related deaths in 2004 (American Heart Association, 2007). The period 
of highest risk is within the first 30 days, depending, in part, on stroke subtype. Almost 
10% of subarachnoid haemorrhage patients die before hospitalisation, with a very high 
fatality rate in the first 2 days. In contrast to cerebral infarction, where deaths begin to 
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occur within a few days to a few weeks, survival following subarachnoid haemorrhage 
has increased over time, partly due to better diagnosis of less severe cases by using 
computed tomography scanning and angiography (Ingall, 2004). The 1-year overall 
survival of stroke is roughly the same for men and women and has improved during the 
last years, thanks to a combination of factors, including a reduction in stroke severity at 
onset associated with increased detection of small, less severe strokes and better care of 
stroke patients. Survival at 5 years is significantly better for transient ischaemic attack 
(TIA) than an ischaemic stroke (Whisnant, 1993). 
In addition to medical factors including previous TIA or stroke, ischaemic heart 
disease or atrial fibrillation, the likelihood of having a favourable outcome decreased 
with increasing age. Apart from biological traits such as age and sex, risk factors for 
stroke may refer to physiological characteristics such as high blood pressure, serum 
cholesterol, fibrinogen; behaviours such as smoking, diet, alcohol consumption, physical 
inactivity; social characteristics like education, social class and ethnicity; and 
environmental factors that may be physical (temperature, altitude), geographical or 
psychosocial. At a population level, blood pressure and tobacco use are the two most 
important modifiable risk factors for stroke due to their strong associations, high 
prevalence and the possibility for intervention (Shinton and Beevers, 1989; Elkind and 
Sacco, 1998). 
As well as producing a high mortality burden, cerebrovascular disease is the leading 
cause of disability in adults, and each year millions of stroke survivors have to adapt to a 
life with restrictions in activities of daily living. Many surviving stroke patients will often 
depend on other people’s continuous support to survive. One measure that takes into 
account the burden due to both deaths and disability for a particular disease is Disability 
Adjusted Life Years (DALYs), which is measured in days of potential life lost due to 
premature death and disability. The WHO Burden of Disease study uses DALYs 
to estimate the burden of disease. There were almost 50 million DALYs lost worldwide 
to stroke in 1999. This is almost 8.4/1,000 people, representing 3.5% of the total burden 
of all diseases. There is significant variation between regions in the total disease burden, 
from around 4.4 to 23.0 DALYs per 1,000 (World Health Organization, 2004). In the 
Family Heart Study of National Heart Lung and Blood Institute, among 108 ischaemic 
stroke survivors who were at least 65 years old, these disabilities were observed at 
6 months after stroke: 50% had some hemiparesis, 30% were unable to walk without 
some assistance, 26% were dependent on activities of daily living, 19% had aphasia, 
35% had depressive symptoms and 26% were institutionalised in a nursing home 
(American Heart Association, 2007). 
A significant improvement in acute stroke morbidity and mortality could be achieved 
by the reorganisation of stroke care services with the goal of rapidly evaluating and 
treating acute stroke patients. Acute ward area with stroke-dedicated beds (at least 80% 
of admitted patients are stroke patients) and dedicated teams (at least one full-time 
physician and nurse were caring exclusively for acute stroke patients), the so-called 
stroke unit (SU), are implemented to face acute stroke patients. Clinical trials and 
meta-analysis have consistently demonstrated the effectiveness of SU services for 
hospitalised stroke patients, reducing the number of survivors who depend on others for 
support either at home or in a healthcare facility. To determine whether admission to an 
SU, rather than a conventional ward, affected the outcome of patients with acute stroke, 
an observational study was conducted in Italy between 2000 and 2004 (Candelise et al., 
2007). Data were collected on about 11,572 acute stroke patients hospitalised within 
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48 hours of the onset of symptoms either in an SU (43%) or in a conventional ward 
(57%). The study showed that there was an association between SU care provided in the 
acute phase of the disease and improvement of stroke outcome. In this setting, SU care 
could reduce in-hospital case fatality and also increase the proportion of patients living 
independently about 2 years after discharge. Provided admission occurs within 48 hours 
of onset, patients with acute stroke should be treated in SU wards with dedicated beds 
and staff, irrespective of age. 
The expected number of new stroke events, based on the WHO stroke estimates and 
the United Nation’s population projections, indicates that there will be an increase in the 
absolute number of stroke events from approximately 1.1 million per year in 2000 to 1.5 
million per year in 2025, even with stable stroke incidence rates. If the exposure to main 
modifiable risk factors of stroke would increase or be controlled, the estimated effect of 
slight increases or decreases in stroke incidence rates (±2% per 5 years) could lead to 
the difference by 2025 of ±150,000 stroke events when compared with stable rates 
(Truelsen et al., 2006). These numbers strongly suggest for intensifying prevention of 
stroke, as improving SUs for treatment and rehabilitative care. 
2.2 Socioeconomic implications of stroke 
Many economic resources in the diagnostic, therapeutic and rehabilitative phases are 
absorbed by stroke involving professionals, institutional and non-institutional facilities. 
The costs of stroke depend on casing mix, types of stroke care provided, age, gender 
and severity. The estimates of the Cost-of-Illness approach provide information that 
describes the resources used and potential resources lost related to stroke. According to 
that, three categories of stroke-related costs may be identified: 
Direct costs are borne by the healthcare system, community and family in directly 
addressing the problem (e.g. hospital care, physicians services, nursing home care, 
drugs); they basically consist of goods and services provided for preventing, diagnosing 
and treating the stroke disease and the medical consequences of it as well as for the 
rehabilitation services. Direct costs also include the out-of-pocket expenditures incurred 
by patient and family. This category of costs is mainly influenced by the length of stay in 
hospital, which largely depends on the severity of stroke and the death after stroke in 
hospital or needs for rehabilitation care and long-term care (Saxena et al., 2006). 
Indirect costs include non-medical societal costs such as productivity losses caused 
by the disease, borne by the individual, family, society and/or employer, such as short-
term absence from work, early retirement or premature mortality. 
Intangible costs are usually the costs of pain, suffering, loss of leisure time, loss of 
companionship and other non-financial impacts. 
In the USA, the direct and indirect cost of cardiovascular diseases has been estimated 
at $431.8 billion in 2007, of which $62.7 billion was attributable to stroke (American 
Heart Association, 2007). Direct costs were about 66% of the stroke costs (hospital cost 
$17.9 billion, nursing home cost $15.2 billion, physicians/other professionals cost $3.5 
billion, medical durable cost $1.2 billion and home healthcare cost $3.8 billion). The 
mean lifetime cost of ischaemic stroke has been estimated at $140,048 including inpatient 
care, rehabilitation and follow-up care essential for lasting deficits. In the baseline 
scenario, the most important cost component for stroke care is the continuing care such as 
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long-term nursing care, community-based care and social support services (Sundberg, 
Bagust and Terént, 2003). The increased use of continuing care and rehabilitation 
services raises the costs of stroke care. Moreover, better diagnosis and more appropriate 
treatments allow reduced unknown strokes relatively more than other types of stroke; as a 
result, some deaths will be avoided and stroke disabilities in the population can be 
expected to increase. 
A summary of selected European studies on stroke costs per patient is shown in 
Table 1 (Truelsen et al., 2006). 
Table 1 A summary of selected studies on costs per patient in some European countries 
Studies Country Cost categories 
Sample size 
(number of patients) 
Costs per patient adjusted 
2004 Euroa
Carod-Artal 
et al. (1999) 
Spain Direct medical
costs 
118 5,435 during the first year 
Ghatnekar 
et al. (2004) 
Sweden Direct and 
indirect costs 
4,357 from the 
nationwide register 
Risks Stroke 
13,903 in direct costs 
during the first year 
Grieve et al. 
(2000) 
UK Direct costs 328 from the South 
London Stroke Register 
7,393 during the first year 
Porsdal 
and 
Boysen 
(1999) 
Denmark Direct medical 
and 
non-medical 
costs 
475 with intracerebral 
haemorrhage (90), 
cerebral infarct or 
unspecified stroke (385) 
9,815 during the first year 
Spieler et al. 
(2002) 
France Direct medical 
costs 
494 20,114 over 18 months 
van Exel 
et al. (2003) 
Netherlands Direct medical 
and 
non-medical 
costs 
598 16,048 over 6 months 
Weimar 
et al. (2003) 
Germany Direct and 
indirect costs 
586 20,239 over 1 year 
Andersson 
et al. (2002) 
Sweden Inpatient costs 
and social 
services 
121 26,557 during the first 
year
Bergman 
et al. (1995) 
Netherlands Lifetime direct 
costs 
24,007 33,604 for women; 28,716 
for men 
Claesson 
et al. (2000) 
Sweden Direct medical 
and non- 
medical costs 
249 25,493 during the first 
year
Dodel et al. 
(2004) 
Germany Direct medical 
and 
non-medical 
costs 
340 admitted for stroke 
(or TIA) 
3,515 for isachemic stroke 
and 5,131 for intracerebral 
haemorrhage 
(per admission) 
Levy et al. 
(2003) 
France Direct medical 
costs 
Patients from CAPRIE 
trial 
6,250 over 2 years 
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Table 1 A summary of selected studies on costs per patient in some European countries 
(continued) 
Studies Country Cost categories 
Sample size 
(number of patients) 
Costs per patient adjusted 
2004 Euroa
Patel et al. 
(2004) 
UK Direct medical 
and 
non-medical 
costs 
447 acute stroke patients 
randomly assigned to 
stroke unit, stroke team 
or domiciliary stroke 
care
First year costs: 16,403 
for stroke unit; 13,648 for 
stroke team; and 9,799 for 
domiciliary stroke care 
Terent et al. 
(1994) 
Sweden Direct and 
indirect costs 
162 + 125 patients in 
two populations 
26,043 during the first 
year and 20,715 during 
the second in the first 
population (N = 162). 
Slightly lower in the 
second one 
Zethraeus 
et al. (1999) 
Sweden Direct medical 
and 
non-medical 
costs 
25 23,666 during the first 
year
Note: aEur Stat (2004a), Eurostat (2004b) and European Central Bank (2004). 
The costs of acute stroke vary throughout European countries depending on the model of 
care adopted: the duration of stay in hospital; daily input from therapists; the use of 
investigations; daily availability of doctors; the costs of employing healthcare 
professionals. 
Several categories of stroke costs could be identified according to organising features 
as: 
1 initial acute hospital stay 
2 rehabilitation unit stay 
3 ambulatory costs 
4 community costs (Grieve et al., 2001b). 
In addition to acute units caring for patients for 7 days after stroke and rehabilitation units 
that admit patients afterwards, integrated SUs identify these functions simultaneously. 
Comparing costs between different wards, SUs are more expensive than traditional 
wards (i.e. general and neurology wards), but have better results in terms of efficacy and 
cost-effectiveness. An Italian study shows that the length of stay in an SU is more 
expensive than the traditional one due to a higher intensity of medical treatments, 
whereas mortality, disability and rehabilitative phase costs are reduced (Miceli, 2002). In 
France, the total cost per patient over 5 years has been estimated €30,983.28 for a 
conventional care unit and €34,683.09 for an SU, and in terms of efficacy, treatment in 
SUs provides a benefit of 2.69 trimesters of survival without disability. The expenditure 
required for conventional care of 120,000 new strokes a year in France would be €3,718 
million over 5 years (31% long-stay institution, 28% rehabilitation unit, 28% home care, 
13% hospital); the corresponding figure for SUs is €4,156 million (34% long-stay 
institution, 25% rehabilitation unit, 29% home care, 12% hospital) (Launois et al., 2004). 
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Apart from hospital costs, other institution care costs as rehabilitation centres costs 
and nursing home costs could be identified. Hospital costs include accommodation costs, 
medication costs, assessment, medical and paramedical treatments, rehabilitation centres 
costs consider primary the accommodation costs as for nursing home costs. In addition 
costs for patients who stay at home could be considered as home care, paramedical care, 
general practitioner visit, cost of medication, home adaptations and assistive devices 
(van Exel et al., 2003). 
The direct costs during the first months after stroke depend on the duration of the stay 
in hospital, and on the characteristics of the patients (age, gender, place of 
residence/having a partner). 
The length of stay in hospital is the greater component of direct cost in stroke 
healthcare; it depends on several factors such as lower risk of mortality, different degree 
of stroke severity and length of waiting lists for nursing homes (Diringer et al., 1999). 
Variations in the lengths of hospital stay affect the mean total costs: centres with average 
stay over 30 days have the highest costs (Grieve et al., 2001a). 
The cost of institution care (hospital, rehabilitation centre and nursing home) grows 
with the degree of disability, specially for ambulatory care (van Exel et al., 2003). 
Treatment of patients with mild and severe disability is the most expensive: within 
30 days of an acute event, the average cost for mild isachemic strokes has been estimated 
as $13,019 and for severe isachemic strokes as $20,346 (4 or 5 on the Rankin Disability 
Scale) (American Heart Association, 2007). Disability due to a stroke event is a crucial 
financial factor as regards to the dimension of increasing problem, the severity of 
disability degree and the sustainability of overall spending. The need for rehabilitation 
services is expected to increase due to the decrease in age standardised mortality rate of 
stroke patients and the increase in ageing population in developed countries. 
Generally, the wait for discharge is too long than the real need for medical treatments, 
so about 10 of the average 28 days to stay in hospital after stroke are estimated to have 
no medical reasons and consequently many blocked beds cannot be used for new patients 
needing acute treatment (van Exel et al., 2003). Managing care factors may improve 
cost-efficiency of care for stroke patients, reducing waiting lists for nursing home and 
home care and for this way discharging patients from expensive hospital beds. A disease 
management in terms of stroke service has to be pursued giving the right care at the right 
time in the right place from the right professional. A stroke service can be defined as ‘a 
regional chain of caregivers: medical, nursing and therapy staff, who together, as a 
network, warrant integrated expert and coherent treatment and care for stroke patients in 
all phases: acute, rehabilitation and chronic of the ailment’ (van Exel et al., 2003). 
3 Approach to neurorehabilitation: an outline of the ADD 
Data shown in previous section suggest the importance of improving the effectiveness of 
the neurorehabilitation process after the occurrence of stroke. 
Functional recovery could be achieved mostly during the first months after the stroke 
event that is essential in terms of motor skill stimulations. In that period, evaluations 
about patients’ conditions and rehabilitation recovery are regularly performed in the 
clinical practice by evaluation scales measuring functionalities or impairment’s level of 
stroke patients. At present, qualitative methods are employed despite the fact that they are 
not so specific and fine to classify each patient based on his/her grade of severity. 
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Moreover, patients assessed with qualitative scales are often grouped together according 
to very broad categories of stroke severity. 
An innovative method for decision support in neurorehabilitation could be achieved 
through the use of ADD (Mazzoleni et al., 2005). ALLADIN is an innovative platform 
for whole-body isometric force measurements, which aims to assess the functional 
recovery outcome in neurorehabilitation and support the clinical decision making towards 
the choice of the best rehabilitative process for each patient. It calculates and predicts the 
functional recovery of stroke patients and makes clinical assessments and quantitative 
measurements easily exchangeable among clinical stroke rehabilitation units. Its purpose 
is to give quantitative measures for assessing functional recovery, to be compared with 
the qualitative methods at present used the clinical practice (e.g. evaluation scales). With 
the description through the natural language, a more detailed description and 
classification of each patient can be performed. 
4 The proposed theoretical/methodological approach 
A theoretical model is proposed in this section with the aim to frame the cost-saving 
implications related to the use of the ALLADIN ADD – once at the best running – for the 
clinical assessment of stroke patients. A traditional approach is compared to the 
ALLADIN one, considering the diagnostic and the rehabilitative steps of the assistive 
route for a stroke patient. Both approaches are graphically represented and summarised in 
Figure 1: 
Figure 1 The methodological approach to ALLADIN 
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Supposing the stroke occurred at t1, a loss of functionality, hypothesised to be 
approximately 50%, happens in the same time. 
It is well established from the medical literature that the first months after the stroke 
are extremely important in terms of recovering functionality. During this period, patient’s 
recovery, if any, will be periodically assessed using evaluation scales, as consequence of 
xi, xz therapeutic strategies established at every tj, j = 1 ? x. After the tx month threshold, 
rehabilitative therapies get quite no incremental effects. 
Moving along a trial-and-error strategy that is the one adopted until the most effective 
treatment, if any, is identified, further adjustments may be introduced in the settled 
therapy: from xj to xw and from xw to xz up to tx time, which is the time limit fixed in the 
model after the stroke event. 
In this example, according to the model, the trial-and-error strategy produces very 
low incremental improvement in the functionality recovery of stroke patient; in the 
proposed example, in fact, the recovery is about 15% (from 50% level of functionality 
after stroke to 65% after treatment) for the therapeutic strategy xi and about 5% (reaching 
the final level of 70% after treatment at time tx) for the therapeutic strategy xw at time tx,
whereas the therapeutic strategy xj which takes place at t2 shows to have practically no 
effect.
The main advantage of the ALLADIN approach is to allow a precise assessment of 
both the severity of stroke and the level of lost functionality at time t1, as long as an 
evaluation of the expected return from different potential therapeutic strategies, so: 
? reducing the uncertainty in the definition of the right therapy 
? allowing early and timely adjustments in the treatment strategy in a kind of fine 
tuning process 
? allowing estimation of the expected level of recovery related to the xi therapeutic 
strategy 
? selecting the most promising one among the x options. 
At the core, the final advantage of the ‘in-progress evaluation’ of the functional recovery 
on which the ALLADIN approach is based is to allow early readjustments in the 
therapeutic strategy in order to identify timely – and within the x month time limit (the 
most valuable months) – the most efficacious treatment. The expected result is a higher 
level of recovered functionality.
It is worth to underline the strong implications of the ALLADIN approach in terms of 
healthcare – and social – costs and cost savings. 
Cost savings rise mainly from the following elements: 
? an early selection of the most promising therapeutic strategy basing on the reduction 
of uncertainty (trial and error implies costs and new costs ?)
? a reduced number of changes in the therapeutic approach 
? a higher final level of recovered functionality (that is minimisation of residual 
disability) 
? a better understanding of the time when to suspend or reduce the therapies because 
no/or very limited incremental benefits may be expected (the judgment about the 
prosecution of inefficacious treatments depends on ethical criteria, financial 
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resources available or on possible psychological positive effects of the therapy 
(placebo effect) in any case, this choice pertains to the healthcare political sphere. 
Cost savings refer to both public and private resources saved mainly as a consequence of 
a lower level of final residual disability. Applying again the Cost-of-Illness approach, 
considerable social cost savings, measured in direct, indirect and intangible costs, come 
from reducing the residual disability of the stroke patient. 
According to forensic medical studies (Bargagna and Busnelli, 1995, 1996, 2001; 
Comandé, 2006), the relationship between the level of disability and its implications 
on the patient’s life is not a linear one. In particular, it has been demonstrated that there 
is an exponential relationship: as the level of disability increases, the negative 
implications on the patient’s life are higher and higher. A decline of conditions in a 
person with a severe level of disability has a more negative impact on his/her life 
conditions than may have the same decline effect on a person with a mild level of 
disability. The negative impact, in terms of marginal damage, increases as the patient 
level of disability increases (Turchetti, 1996, 2001; Comandé and Turchetti, 2001; 
Turchetti and Labella, 2006). 
If we consider that the costs of taking care of a disabled person grow in accordance 
with the negative effects on life conditions due to the disability decline, we can assert that 
the usefulness of ALLADIN (that is expected to allow the reaching of a higher final level 
of functionality recovered) in terms of socioeconomic savings increases as the level of 
disability increases (this relationship is graphically represented below). 
The impact of an increasing level of disability on human life and the related increase 
in the cost of taking care of the disabled person show that the impact varies with the level 
of disability. In particular, the same increase of 5% does not have the same economic 
effect if added to different starting levels of disability. An increase in disability from 25% 
to 30% (D1) will lead to an increase in cost of C1 whereas an increase from 75% to 80% 
(D2) will lead to a larger increase, namely, C2 (Figure 2). 
Figure 2 Relationship between levels of disability and the cost for taking care of a disabled 
person 
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Therefore, in the theoretical approach proposed, we underline that an innovative 
diagnostic device as ALLADIN is always very useful, but its importance is higher in 
severe and very severe stroke than in stroke with a low level of severity; the savings in 
social costs increase as stroke severity increases. 
The monetary evaluation of these savings is deeply country specific, and a further 
analysis would be interesting to be run. 
5 Conclusions 
The paper discusses a theoretical model for the assessment of social and economic 
benefits of a new neurorehabilitative technology allowing an in-progress evaluation of 
the diagnostic and the rehabilitative steps alongside the assistive route for a stroke patient 
if compared to the trial-and-error strategy pursued by a traditional one. 
The model points out the potential social cost saving related to the application of the 
innovative technology for neurorehabilitation in stroke. Besides the direct cost savings, 
mainly related to a reduced number of changes in the therapeutic approach and to a better 
understanding of the time when to suspend or reduce the therapies, considerable social 
cost savings – both in public and private resources – measured in direct, indirect and 
intangible costs come from reducing the residual disability of the stroke patient. 
The proposed theoretical approach is applied to the use of the ADD as an innovative 
technology in the field of post-stroke neurorehabilitation diagnostic and assessment 
process, but it could be generalised to both robot-mediated rehabilitation therapies and 
other diseases involving different levels of disabilities, such as neurological pathologies. 
References 
American Heart Association (2007) ‘Heart disease and stroke statistics’, Available at: 
http://www.americanheart.org/. 
Andersson, A., Levin, L.A., Oberg, B. and Mansson, L. (2002) ‘Health care and social welfare 
costs in home-based and hospital-based rehabilitation after stroke’, Scandinavian Journal of 
Caring Sciences, Vol. 16, pp.386–392. 
Bargagna, M. and Busnelli F.D. (2001) La Valutazione del Danno alla Salute: Profili Giuridici, 
Medico-Legali ed Assicurativi. Padova, Italy: CEDAM. 
Bargagna, M. and Busnelli, F.D. (1995) La Valutazione del Danno alla Salute: Profili Giuridici, 
Medico-Legali ed Assicurativi. Padova, Italy: CEDAM. 
Bargagna, M. and Busnelli, F.D. (1996) Rapporto sullo stato della giurisprudenza in tema di danno 
alla salute. Padova, Italy: CEDAM. 
Bergman, L., van der Meulen, J.H., Limburg, M. and Habbema, J.D. (1995) ‘Costs of medical care 
after firstever stroke in The Netherlands’, Stroke Vol. 26, pp.1830–1836. 
Brainin, M., Bornstein, N., Boysen, G. and Demarin, V. (2000) ‘Acute neurological stroke care in 
Europe: results of the European Stroke Care Inventory’, European Journal of Neurology,
Vol. 7, pp.5–10. 
Candelise, L., Gattinoni, M., Bersano, A., Micieli, G., Sterzi, R. and Morabito, A. (2007) 
‘Stroke-unit care for acute stroke patients: an observational follow-up study’, Lancet, Vol. 27, 
No. 369, pp.299–305. 
Carod-Artal, F.J., Egido-Navarro, J.A., Gonzalez-Gutierrez, J.L. and Varela de Seijas, E. (1999) 
‘Direct cost of cerebrovascular disease during the first year of followup’, Rev Neurol, Vol. 28, 
pp.1123–1130. 
      
      
   260 G. Turchetti et al.    
      
      
      
Claesson, L., Gosman-Hedstrom, G., Johannesson, M., Fagerberg, B. and Blomstrand, C. (2000) 
‘Resource utilization and costs of stroke unit care integrated in a care continuum: A 1-year 
controlled, prospective, randomized study in elderly patients: the Goteborg. 70+ Stroke 
Study’, Stroke, Vol. 31, pp.2569–2577. 
Comandé, G. (2006) Gli strumenti della precauzione: nuovi rischi, assicurazione e responsabilità.
Milano, Italy: Giuffrè. 
Comandé, G. and Turchetti, G. (2001) ‘Il disegno di legge sul danno biologico presentato 
dal Governo: il suo impatto sistematico e il sistema tabellare’, in M. Bargagna 
and F.D. Busnelli (Eds.) La Valutazione del Danno alla Salute: Profili Giuridici, 
Medico-Legali ed Assicurativi. Padova, Italy: CEDAM. 
Di Carlo, A., Launer, L.J., Breteler, M.M., Fratiglioni, L., Lobo, A., Martinez Lage, J., Schmidt, R. 
and Hofman, A. (2000) ‘Frequency of stroke in Europe: a collaborative study of 
population-based cohorts. ILSA Working Group and the Neurologic Diseases in the Elderly 
Research Group. Italian Longitudinal Study on Aging’, Neurology, Vol. 54, S28–S33. 
Diringer, M.N., Edwards, D.F., Mattson, D.T., Akins, P.T., Sheedy, C.W., Hsu, C.Y. and 
Dromerick, A.W. (1999) ‘Predictors of acute hospital costs for treatment of ischemic stroke in 
an academic center’, Stroke, Vol. 30, pp724–728. 
Dodel, R., Haacke, C., Zamzov, K. and Pawelzik, S. (2004) ‘Resource utilization and cost of stroke 
unit care in Germany’, Value Health, Vol. 7, pp.144–152. 
Elkind, M. and Sacco, R. (1998) ‘Stroke risk factors and stroke prevention’, Seminars in 
Neurology, Vol. 18, pp.429–440. 
European Central Bank (2004) Statistics. Available at: http://www.ecb.int/stats/exchange/eurofxref/ 
html/index.en.html. 
Eurostat (2004a) Economy and Finance. Comparative price levels. Eurostat Yearbook 2004.
Brussels: Eurostat. 
Eurostat (2004b) Economy and Finance. Harmonised Annual Average Consumer Price Indices. 
Eurostat Yearbook 2004. Brussels: Eurostat. 
Feigin, V.L., Lawes, C.M., Bennett, D.A. and Anderson, C.S. (2003) ‘Stroke epidemiology: 
a review of population-based studies of incidence, prevalence, and case-fatality in the late 
20th century’, Lancet Neurology, Vol. 2, pp.43–53. 
Ghatnekar, O., Persson, U., Glader, E. and Terent, A. (2004) ‘Cost of stroke in Sweden: an 
incidence estimate’, Int. J. Technology Assessment in Health Care, Vol. 20, pp.375–380. 
Grieve, R., Dundas, R., Beech, R. and Wolfe, C. (2001a) ‘The development and use of a method to 
compare the costs of acute stroke across Europe’, Age and Ageing, Vol. 30, pp.67–72. 
Grieve, R., Hutton, J., Bhalla, A., Rastenyte, D., Ryglewicz, D., Sarti, C., Lamassa, M., Giroud, M., 
Dundas, R. and Wolfe, C.D.A. (2001b) ‘A comparison of the costs and survival of hospital-
admitted stroke patients across europe’, Stroke, Vol. 32, pp.1684–1691. 
Hachinski, V. (2002) ‘Stroke: the next 30 years’, Stroke, Vol. 33, No. 1, pp.1–4. 
Ingall, T. (2004) ‘Stroke – incidence, mortality, morbidity and risk’, Journal of Insurance 
Medicine, Vol. 36, pp.143–152. 
Jorgensen, H.S., Nakayama, H., Raaschou, H.O. and Olsen, T.S. (1999) ‘Stroke. Neurologic and 
functional recovery the Copenhagen Stroke Study’, Physical Medicine and Rehabilitation 
Clinics of North America, Vol. 10, No. 4, pp.887–906. 
Launois, R., Giroud, M., Mégnigbêto, A.C., Le Lay, K., Présenté, G., Mahagne, M.H., Durand, I. 
and Gaudin, A.F. (2004) ‘Estimating the cost-effectiveness of stroke units in France compared 
with conventional care’, Stroke, Vol. 35, pp.770–775. 
Levy, E., Gabriel, S. and Dinet, J. (2003) ‘The comparative medical costs of atherothrombotic 
disease in European countries’, Pharmacoeconomics, Vol. 21, pp.651–659. 
Mazzoleni, S., Van Vaerenbergh, J., Toth, A., Munih, M., Guglielmelli, E. and Dario, P. (2005) 
‘ALLADIN: a novel mechatronic platform for assessing post-stroke functional recovery’, 
Paper presented in the Proceedings of the International Conference on Rehabilitation 
Robotics, Chicago, IL, pp.156–159. 
      
      
   Innovation in rehabilitation technology 261    
      
      
      
Miceli, G. (2002) ‘Economia Sanitaria delle Stroke Unit’, The Italian Stroke Forum Newsletter,
Vol. 3 No. 2, p.4. 
Patel, A., Knapp, M., Perez, I., Evans, A. and Kalra, L. (2004) ‘Alternative strategies for stroke 
care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled 
trial’, Stroke, Vol. 35, pp.196–203. 
Porsdal, V. and Boysen, G. (1999) ‘Costs of health care and social services during the first 
year after ischemic stroke’, Int. J. Technology Assessment in Health Care, Vol. 15, No. 3, 
pp.573–584. 
Saxena, S.K., Ng, T.P., Yong, D., Fong, N.P. and Gerald, K. (2006) ‘Total direct cost, length of 
hospital stay, institutional discharges and their determinants from rehabilitation settings in 
stroke patients’, Acta Neurologica Scandinava, Vol. 114, pp.307–314. 
Shinton, R. and Beevers, G. (1989) ‘Meta-analysis of relation between cigarette smoking and 
stroke’, British Medical Journal, Vol. 298, pp.789–795. 
Spieler, J.F., Lanoe, J.L. and Amarenco, P. (2002) ‘Socioeconomic aspects of postacute care for 
patients with brain infarction in France’, Cerebrovasc Dis, Vol. 13, pp.132–141. 
SPREAD (2005) Stroke Prevention and Educational Awareness Diffusion (4th ed.), Milano, Italy: 
Catel – Hyperphar Group SpA. 
Sundberg, G., Bagust, A. and Terént, A. (2003) ‘A model for costs of stroke service’, Health 
Policy, Vol. 63, pp.81–94. 
Terent, A., Marke, L.A., Asplund, K., Norrving, B., Jonsson E. and Wester, P.O. (1994) ‘Costs of 
stroke in Sweden. A national perspective’, Stroke Vol. 25, pp.2363–2369. 
Truelsen, T., Begg, S. and Mathers, C. (2003) The Global Burden of Cerebrovascular Disease.
Geneva: World Health Organization. 
Truelsen, T., Piechowski-Jozwiak, B., Bonita, R., Mathers, C., Bogousslavsky, J. and Boysen, G. 
(2006) ‘Stroke incidence and prevalence in Europe: a review of available data’, European 
Journal of Neurology, Vol. 13, pp.581–598. 
Turchetti, G. (1996) ‘Gli sviluppi dello studio sulla determinazione del valore monetario base del 
punto di invalidità’, in M. Bargagna and F.D. Busnelli (Eds), Rapporto sullo stato della 
giurisprudenza in tema di danno alla salute. Padova, Italy: CEDAM, pp.171–201. 
Turchetti, G. (2001) ‘Una Ipotesi di Costruzione della Tabella dei Valori Monetari Base del Punto 
di Invalidità’, in M. Bargagna and F.D. Busnelli (Eds) La Valutazione del Danno alla Salute: 
Profili Giuridici, Medico-Legali ed Assicurativi. Padova, Italy: CEDAM, pp.629–669. 
Turchetti, G. and Labella, B. (2006) ‘L’innovazione nelle tecnologie biomediche tra rischio, 
incertezza, precauzione e gestione’, in G. Comandé, (Eds), Gli strumenti della precauzione: 
nuovi rischi, assicurazione e responsabilità. Milano, Italy: Giuffrè, pp.367–395. 
van Exel, J., Koopmanschap, M.A., van Wijngaarden J.D.H. and Scholte op Reimer W. J.M. (2003) 
‘Costs of stroke and stroke services: determinants of patient costs and a comparison of costs of 
regular care and acre organised in stroke services’, Cost Effectiveness and Resource 
Allocation, Vol. 1, pp.1–11. 
Weimar, C., Weber, C., Wagner, M., Busse, O., Haberl, R.L., Lauterbach, K.W. and Diener, H.C. 
(2003) ‘Management patterns and health care use after intracerebral hemorrhage. A cost-of-
illness study from a societal perspective in Germany. Cerebrovasc Dis, Vol. 15, pp.29–36. 
Whisnant, J. (1993) ‘Natural history of transient ischemic attack and ischemic stroke’, 
in J. Whisnant (Ed), Stroke: Population, Cohorts, and Clinical Trials. Oxford: 
Butterworth-Heinemann Ltd., pp.135–153. 
World Health Organization (2004) ‘The atlas of heart disease and stroke’, Available at: 
http://www.who.int/cardiovascular_diseases/resources/atlas/en/. 
Zethraeus, N., Molin, T., Henriksson, P. and Jonsson, B. (1999) ‘Costs of coronary heart disease 
and stroke: the case of Sweden’, Journal of Internal Medicine, Vol. 246, pp.151–159. 
